This clinical trial is focused on studying the effects of adding a medication called durvalumab after initial treatment in patients with early-stage, operable non-small cell lung cancer (NSCLC). The study aims to understand if this additional treatment can improve the time patients remain free from cancer after surgery. The initial treatment involves a combination of chemotherapy and durvalumab, followed by surgery to remove the cancer.

Participants in the study will receive treatments through an intravenous infusion, which means the medication is given directly into a vein. The medications used in the study include cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, which are all types of chemotherapy drugs. These drugs work by targeting and killing cancer cells. The study will also use durvalumab, an immunotherapy drug that helps the immune system recognize and attack cancer cells.

The study will take place over a period of time, with participants receiving treatment for up to 16 weeks. The goal is to determine if adding durvalumab after the initial treatment can help prevent the cancer from returning. Participants will be monitored throughout the study to assess their response to the treatment and any side effects they may experience. The study is designed to provide valuable information on improving treatment outcomes for patients with early-stage NSCLC.